TScan Therapeutics (NASDAQ:TCRX) Shares Up 1.8% – What’s Next?

TScan Therapeutics, Inc. (NASDAQ:TCRX)’s stock price traded up 1.8% on Wednesday . The stock traded as high as $1.1750 and last traded at $1.14. 329,995 shares were traded during mid-day trading, a decline of 32% from the average session volume of 486,136 shares. The stock had previously closed at $1.12.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on TCRX shares. Morgan Stanley downgraded TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research report on Friday, November 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Wednesday, October 8th. HC Wainwright lowered their target price on shares of TScan Therapeutics from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Needham & Company LLC reduced their price target on shares of TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, November 4th. Finally, BTIG Research cut shares of TScan Therapeutics from a “buy” rating to a “neutral” rating in a research report on Tuesday, November 4th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $6.60.

TScan Therapeutics Price Performance

The company has a 50 day moving average of $1.05 and a 200 day moving average of $1.56. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.44 and a current ratio of 6.44. The stock has a market capitalization of $64.70 million, a price-to-earnings ratio of -1.02 and a beta of 1.04.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.07. TScan Therapeutics had a negative return on equity of 73.33% and a negative net margin of 1,692.96%.The business had revenue of $2.51 million during the quarter, compared to analysts’ expectations of $1.98 million. As a group, equities research analysts anticipate that TScan Therapeutics, Inc. will post -1.12 EPS for the current year.

Insider Buying and Selling

In other news, major shareholder Lynx1 Capital Management Lp acquired 80,069 shares of the firm’s stock in a transaction dated Friday, December 19th. The stock was acquired at an average cost of $0.90 per share, with a total value of $72,062.10. Following the transaction, the insider owned 7,937,416 shares in the company, valued at approximately $7,143,674.40. This trade represents a 1.02% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders have purchased 161,801 shares of company stock worth $145,621. Insiders own 4.35% of the company’s stock.

Institutional Trading of TScan Therapeutics

Several institutional investors have recently modified their holdings of TCRX. BVF Inc. IL lifted its holdings in shares of TScan Therapeutics by 6.9% in the 2nd quarter. BVF Inc. IL now owns 5,226,074 shares of the company’s stock valued at $7,578,000 after purchasing an additional 336,600 shares during the last quarter. Vanguard Group Inc. increased its position in TScan Therapeutics by 7.8% during the third quarter. Vanguard Group Inc. now owns 2,317,916 shares of the company’s stock worth $4,219,000 after buying an additional 168,540 shares during the period. Aberdeen Group plc lifted its stake in TScan Therapeutics by 31.8% in the fourth quarter. Aberdeen Group plc now owns 1,785,241 shares of the company’s stock valued at $1,785,000 after buying an additional 430,421 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of TScan Therapeutics by 14.9% in the third quarter. Two Sigma Investments LP now owns 419,404 shares of the company’s stock valued at $763,000 after acquiring an additional 54,370 shares during the period. Finally, Citadel Advisors LLC grew its position in shares of TScan Therapeutics by 78.4% during the third quarter. Citadel Advisors LLC now owns 390,747 shares of the company’s stock worth $711,000 after acquiring an additional 171,760 shares during the last quarter. Hedge funds and other institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.